3 - Procaps Group, S.A. (0001863362) (Issuer)

3 - Procaps Group, S.A. (0001863362) (Issuer)

3 - Procaps Group, S.A. (0001863362) (Issuer)

3 - Procaps Group, S.A. (0001863362) (Issuer)

Procaps Group (NASDAQ:PROC) ("Procaps"). Having completed the last ordinary meeting of 2023 on December 19th in which Ruben Minski acted as CEO of the Procaps Group for the last time, and taking into account that as of January 15th, 2024 he will take over as Executive Chairman of the Board, which resulted from a planned and communicated process to the market since February of this year, we would like to express our appreciation to Ruben for his inspiring and visionary leadership that has allowed Procaps to be a leading organization in the pharmaceutical sector in the Region today, recognized and valued in the market by the different stakeholders. Throughout his career in the Organization,

Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today a strategic leadership transition as Ruben Minski, founder and CEO of Procaps prepares to transition from the role of Chief Executive Officer to focus exclusively on his role as Executive Chairman of the Board, and the appointment of Jose Antonio Vieira as the new Chief Executive Officer of Procaps Group. The transition will be effective January 15, 2024. After over 45 years of visionary leadership and dedicated service, Ruben Minski has played a pivotal role in Procaps' growth and success, transforming it into a global leader in pharmaceutical innovation. Under

Experienced Pharma Professional Brings Wealth of International Industry and Governance Experience to Board Procaps Group (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced the appointment of one new member to its Board of Directors (the "Board"). On October 23, 2023, the Board appointed Sandra Sánchez y Oldenhage as a Director to fill the current vacancy on the Board, effective immediately and for a period ending at its annual general meeting of shareholders for the fiscal year ended December 31, 2023. Sandra Sánchez y Oldenhage has over 35 years' experience in steering mature, start-up, and turn-around/re

Pharmaceutical Industry and Investor Relations Veteran to Lead Capital Markets Communications Strategy Procaps Group (NASDAQ:PROC), a leading integrated international healthcare and pharmaceutical company, today announced the appointment of Melissa Angelini as Investor Relations Director, effective February 1, 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220128005310/en/Melissa Angelini, Procaps Group Investor Relations Director (Photo: Business Wire) Melissa Angelini is a seasoned executive with over 15 years of experience in capital markets and investor relations with healthcare and pharmaceutical companies. She has ex

Net Revenues Increased 5% in 9M23 Year-over-Year on a Constant Currency Basis, Driven by 13% RX Growth Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company, today announced its financial results for the three months ended September 30, 2023 ("3Q23") and the nine months ended September 30, 2023 ("9M23"). Financial Highlights 3Q23 & 9M23 Net revenues totaled $118 million for 3Q23, positively impacted by the performance of RX and OTC portfolios, offset by lower CDMO revenues. On a constant currency basis, net revenues increased by 2% in 3Q23. For 9M23, net revenues totaled $313 million, an incre

Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23"). Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call. About Procaps Group Procaps Group, S.A. ("Procaps") (NASDAQ:PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplie

Company to Host Conference Call on Thursday November 16, 2023 at 10:30 a.m. Eastern Time Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023. The Company will host a conference call and webcast on Thursday, November 16, 2023, at 10:30 a.m. Eastern time, to discuss the third quarter and nine months 2023 results. To access the call, please use the following information: Date: Thursday, November 16, 2023 Time: 10:30 a.m. ET Webcast: Cli

Net Revenues Increased 7% in 1H23 Year-over-Year, on a Constant Currency Basis, Signaling Positive Performance of Rx Products Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company, today announced its financial results for the three months ended June 30, 2023 ("2Q23") and the six months ended June 30, 2023 ("1H23"). "Amidst a challenging 2Q23, we are accelerating our strategic plan, bolstered by operational agility. While short-term impacts were expected, we believe our proactive approach to cost-cutting positions us for a resilient 4Q23. We are addressing cash flow concerns, adapting pricing str

Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will report its results for the second quarter and six months ended June 30, 2023, before market opens on Tuesday, September 5, 2023. The Company will host a conference call and webcast at 11:00 a.m. Eastern time, on the same day, to discuss the second quarter and first half 2023 results. To access the call, please use the following information: Date: Tuesday, September 5, 2023 Time: 11:00 a.m. ET Webcast: Click here to access Toll Free dial-in number: 1-844-204-8586 Toll/Internationa

Constant Currency Net Revenues Increased 7% Year-over-Year in 2022, With Strong Demand of RX and Softgel Portfolios, Offset by Clinical Specialty Covid Portfolio Preliminary Results for 1Q23 Show a Significant Rebound from 4Q22 Performance, Company Expects to Reach at Least High Single-Digit Growth in Adjusted EBITDA Management Reaffirms Preliminary FY2023 Net Revenue and Adjusted EBITDA Guidance Multiple Value-Creation Initiatives Implemented and On Track to Achieve Up to $15 million of Targeted Recurring Savings Company to Host Conference Call and Webcast Monday, May 15, 2023 at 10:00am Eastern Time Procaps Group S.A. (NASDAQ:PROC) ("Procaps"), a leading integrated international

MIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today that it will file its Form 20-F and publish its Full Year 2022 Earnings Release before May 15th. The delay in filing the 2022 Form 20-F is because additional time is necessary to prepare and complete the internal review of the Company's financial statements for the year ended December 31, 2022. Procaps is making every effort to file its 2022 Form 20-F as soon as practicable. In conjunction with the 20-F filing, Procaps will publish its Full Year 2022 Earnings Release and ho

Reports Preliminary Financial Estimates for Net Revenue and Adjusted EBITDA for Full Year 2022 Realigns Board of Directors to Focus on Profitable Growth Announces $5M+ Share Repurchase Program Commences $15MM Cost Reduction Plan to Improve Margins and Financial Performance 20-F & Conference Call for Q4 and FY 2022 Financial Results Expected to Occur in March 2023 MIAMI and BARRANQUILLA, Colombia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued a letter to shareholders from Ruben Minski, Chairman of the Board and CEO of Procaps, including preliminary select f

MIAMI and BARRANQUILLA, Colombia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Procaps Group S.A. (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its financial results for the three months ended September 30, 2022 ("3Q22") and the nine months ended September 30, 2022 ("9M22"). "Demand remains robust for RX and consumer health products as well as for all our CDMO products, and gross margin remained strong despite the challenging macro scenario we have been facing. We have continued to invest and prepare the company for the organic and inorganic growth that is about to come, and we expect to see continued revenue growth and improved ope

MIAMI and BARRANQUILLA, Colombia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that it expects to report its results for the third quarter ended September 30, 2022, after the market closes on Monday, November 14, 2022. The Company expects to host a conference call and webcast at 04 p.m. Eastern time, on November 16, 2022.To access the call, please use the following information: Date:Wednesday, November 16, 2022Time:04 p.m. ETToll Free dial-in number:1-844-204-8586Toll/International dial-in number:1-412-317-6346Procaps HD Phone:https://bit.ly/PROCHDPHONEConference ID:Procaps Group

Procaps Group (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it has received a letter from the Nasdaq Stock Market, dated May 16, 2024 (the "Delinquency Letter"), notifying the Company that it is not in compliance with the requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) because it did not timely file its annual report on Form 20-F for the year ended December 31, 2023 (the "2023 20-F").

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. The following stocks are considered to be notable value stocks in the healthcare sector: Kiora Pharmaceuticals (NASDAQ:KPRX) - P/E: 0.84 Procaps Gr (NASDAQ:PROC) - P/E: 6.16 InMode (NASDAQ:INMD) - P/E: 9.55 Alkermes (NASDAQ:ALKS) - P/E: 9.56 Syros Pharmaceuticals (NASDAQ:SYRS) - P/E: 7.97 Kiora Pharmaceuticals saw a decrease in earnings per share from -0.79 in Q2 to $-0.89 now. Procaps Gr saw a decrease in

The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. The following stocks are considered to be notable value stocks in the healthcare sector: Organon (NYSE:OGN) - P/E: 4.4 BioNTech (NASDAQ:BNTX) - P/E: 7.47 TherapeuticsMD (NASDAQ:TXMD) - P/E: 0.52 Innoviva (NASDAQ:INVA) - P/E: 6.93 Procaps Gr (NASDAQ:PROC) - P/E: 5.84 Or

Procaps Group (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is conducting a process to explore strategic alternatives to maximize shareholder value. As part of this process, the Company plans to consider a wide range of options, all to accelerate growth and optimize shareholder value.As previously communicated, Jose Vieira, Procaps newly appointed CEO, will continue to develop a detailed strategic plan, working closely with Ruben Minski, Executive Chairman, and the Company's Board of Directors. Ruben Minski noted: "We are thrilled with Jose Vieira's progress in developing strategies to set Procap

U.S. stocks were lower, with the Dow Jones index dipping more than 500 points on Tuesday. Shares of Ecolab Inc. (NYSE:ECL) rose during Tuesday’s session after the company reported better-than-expected fourth-quarter financial results and issued first-quarter adjusted EPS guidance above estimates. Ecolab posted adjusted earnings of $1.55 per share, beating market estimates of $1.54 per share. The company’s quarterly sales came in at $3.94 billion versus estimates of $3.93 billion, according to data from Benzinga Pro. Ecolab shares gained 6.4% to $216.00 on Tuesday. Here are some other big stocks recording gains in today’s session. Whole Earth Brands, Inc. (NASDAQ:FREE) gained 35.3% to

What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. Below is a list of notable value stocks in the healthcare sector: Kiora Pharmaceuticals (NASDAQ:KPRX) - P/E: 1.01 Voyager Therapeutics (NASDAQ:VYGR) - P/E: 6.42 Quoin Pharmaceuticals (NASDAQ:QNRX) - P/E: 2.39 Procaps Gr (NASDAQ:PROC) - P/E: 7.27 Solid Biosciences (NASDAQ:SLDB) - P/E: 0.1 Kiora Pharmaceuticals's earnings per share for Q3 sits at $-0.89, whereas in Q2, they were at -0.79. Most recently, Voy

Procaps Group (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued a letter to shareholders from Jose Vieira, CEO of Procaps.Dear Shareholders,I am honored to address you as the newly appointed CEO of Procaps Group. In my initial three weeks, I have immersed myself in understanding the intricacies of Procaps Group. This journey involves recognizing its unique strengths, identifying areas for improvement, and, most importantly, pinpointing avenues for growth.My commitment to this amazing company is unwavering, and my goal is to further strengthen our culture of transparency, innovation, and collaboration, fostering a w

Dear Shareholders,We became aware on Saturday, January 13, 2024, that the online voting instructions related to the upcoming General Meeting of Shareholders of the Company scheduled for January 22, 2024, were incorrect. Notwithstanding the Company's diligent review of all relevant materials, a third party unilaterally included on the online version an inaccurate statement that the Board of Directors of the Company had recommended a vote in favor of the proposals to be voted on. We are currently investigating the reason for such erroneous inclusion and have requested a correction of all inaccurate statements.We are discussing next steps with Company's counsel but wanted all shareholders of th

What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. Below is a list of notable value stocks in the healthcare sector: Agile Therapeutics (NASDAQ:AGRX) - P/E: 0.25 Panbela Therapeutics (NASDAQ:PBLA) - P/E: 0.0 Procaps Gr (NASDAQ:PROC) - P/E: 8.96 Exicure (NASDAQ:XCUR) - P/E: 0.43 Zymeworks (NASDAQ:ZYME) - P/E: 3.4 Agile Therapeut